11:58 PM
md arif
The swine flu virus will spread in 2010 thru 2013. The media circus may have quieted down, but more than 70 countries now report cases of the virus and the number is growing.
The World Health Organization is has raised its pandemic alarm to full alert for the first time since 1968.
One million Americans are already infected. The X factor is that epidemiologists don't know how it will react when it mixes with regular seasonal flu, which already kills 36,000 Americans a year.
Public health officials say an influenza pandemic could kill 71 million people worldwide. To fend off catastrophe, the U.S. and other governments around the world are spending billions to stockpile antiviral drugs and vaccines.
The U. S. government has already set aside $1 billion to develop the vaccine to fight the virus. A nationwide H1N1 vaccination program will cost between $3 billion and $18 billion.
The strong government response to this pandemic could lead to big profits for several drug makers. You'll find their names in The Investment Opportunities for 2010 thru 2013.
Roche, Novartis, GlaxoSmithKline and Sanofi-Aventis are all working on vaccines. It's too soon to tell who will win the fattest contracts. But they are all so large that even a billion-dollar contract won't do much for the bottom line.
In contrast, the CDC recently awarded a $35 million development contract to a small biotech company. This is the sort of company you should be looking to buy.
We especially like a small clinical-stage biopharmaceutical company based in Maryland. When the swine flu story hit the news in April, this small flu-vaccine maker was trading for 81 cents. A day later the stock hit $3.88.
That's a +379% jump in price overnight. A few small fortunes were made from this one simple fear trade.
After surging as high as $7.79, this stock is now backing in the $4 range. If the swine flu hits 40% of the U.S. population, as the Centers for Disease Control projects could happen, this stock could go on a rocket ride. You'll get full details on it in your free copy of The Investment Opportunities for 2010 thru 2013.
As the healthcare debate reaches fever pitch, it's clear that big changes are coming. As with any massive regulatory overhaul, some companies are cowering in fear of the proposals -- but others are chomping at the bit.
Partisan rancor aside, we all have a common enemy in spiraling costs. So it stands to reason that companies trimming fat from the system will have powerful allies on both sides of the political aisle.
That makes the healthcare IT sector a safe bet. But stocks in this niche are already pricey. For real upside we like companies working to develop generic substitutes for biotech drugs. These medicines save lives, but can also be prohibitively expensive (cancer drug Avanti costs up to $100,000 annually).
We think a resistance to cheaper biotech equivalents will soon melt away. Generic prescriptions now account for almost 70% of all pills taken nationwide. These inexpensive alternatives have saved more than $730 billion over the past decade.
Biotech's have fended off generic imitators until now, but the copycats are about to break through. Bipartisan legislation pushing for a formal FDA approval pathway has been introduced in both the house and Senate.
By next year, we'll see the FDA approving biogenetic medicines in the United States. The lure of shaving off one-third of the $40 billion we spend on biotech drugs each year will prove irresistible.
The investment implications are huge. Washington's move will have a big impact on biotech companies like Amgen and Genentech, as well as traditional drug makers like Merck who want to get into generic biotech.
In the Investment Opportunities for 2010 thru 2013 we profile the company that is best positioned of all to profit from the FDA's move. A regulatory green light could send this stock soaring. Investing in The High Risk Market in the Future is Where the Money will be from 2010 thru 2013. What might be Happen Next Who Know???.........................?
Posted in: 
0 comments:
Post a Comment